Compare NIU & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | CRBU |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 138.3M |
| IPO Year | 2018 | 2021 |
| Metric | NIU | CRBU |
|---|---|---|
| Price | $1.89 | $0.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.55 | ★ $5.75 |
| AVG Volume (30 Days) | 155.7K | ★ 4.7M |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.29 | $145.34 |
| Revenue Next Year | $22.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.79 | $0.44 |
| 52 Week High | $4.53 | $3.53 |
| Indicator | NIU | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 24.04 |
| Support Level | $1.81 | $0.44 |
| Resistance Level | $2.04 | $1.72 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 18.18 | 12.99 |
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.